Beijing Enhua Pharmaceutical Research Institute

Beijing Enhua Pharmaceutical Research Institute is the specialized research and development arm of Jiangsu Nhwa Pharmaceutical Co., Ltd., a leading Chinese pharmaceutical company focused on the Central Nervous System (CNS). Based in Beijing, the institute serves as a key innovation platform for the discovery and development of therapeutics for cardiovascular and cerebrovascular diseases, as well as advanced CNS indications. The institute manages a diverse pipeline of over 20 innovative drug candidates, including small molecules and biologics, through independent research and strategic global partnerships with companies such as Trevena, I-Mab, and Lundbeck. Its portfolio includes advanced programs for acute pain, Parkinson's disease psychosis, depression, and Alzheimer's disease. As a core component of the Nhwa Group, the institute leverages collaborations with prestigious academic and military research institutions to drive the company's expansion into high-growth therapeutic areas.